Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells

Although multitargeted tyrosine kinase inhibitor sunitinib has been used as first‐line therapeutic agent against metastatic renal cell carcinoma (mRCC), the molecular mechanism and functional role per se for its therapeutic performance remains obscure. Our present study revealed that sunitinib‐treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Zhu, Yu, Xu, Le, Zhang, Jianping, Hu, Xiaoyi, Liu, Yujun, Yin, Hankun, Lv, Tao, Zhang, Heng, Liu, Li, An, Huimin, Liu, Haiou, Xu, Jiejie, Lin, Zongming
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657144/
https://ncbi.nlm.nih.gov/pubmed/23578198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12176
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados